Dec 02, 2021 / NTS GMT
Jun Suzuki - Teijin Limited - CEO, President, Member of Advisory Board & Representative Director
This is Jun Suzuki of Teijin. Thank you for joining us in our regenerative medicine business briefing today. It gives us a great pleasure to have so many participants.
As you are aware, on January 29 of this year, Teijin announced the Board decision to acquire the shares in J-TEC through a tender offer. The stock purchase was carried out from February 1 to March 2 and was successfully completed as originally planned, making Teijin the parent company of J-TEC. Following the closing in March, we embarked on more detailed official studies on how best to improve the corporate value of both Teijin and J-TEC.
When we made the internal decision to join hands with J-TEC more than a year ago, we already had a clear vision regarding the direction of the business that is to pursue regenerative medicine using autologous cell as the alternate of tailor-made medicine. Furthermore, we did envision that this business could make the big leap through leveraging Teijin's capabilities in health care, materials
Teijin Ltd Regenerative Medicine Business Briefing Transcript
Dec 02, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers